WO2019113803A1 - 用于抑制eb病毒相关肿瘤的化合物及其制备方法和用途 - Google Patents

用于抑制eb病毒相关肿瘤的化合物及其制备方法和用途 Download PDF

Info

Publication number
WO2019113803A1
WO2019113803A1 PCT/CN2017/115736 CN2017115736W WO2019113803A1 WO 2019113803 A1 WO2019113803 A1 WO 2019113803A1 CN 2017115736 W CN2017115736 W CN 2017115736W WO 2019113803 A1 WO2019113803 A1 WO 2019113803A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
amino
methyl
carboxy
compound
Prior art date
Application number
PCT/CN2017/115736
Other languages
English (en)
French (fr)
Inventor
粟武
王蒲
王伟
成哲弘
房丽晶
武春雷
Original Assignee
深圳先进技术研究院
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 深圳先进技术研究院 filed Critical 深圳先进技术研究院
Priority to PCT/CN2017/115736 priority Critical patent/WO2019113803A1/zh
Publication of WO2019113803A1 publication Critical patent/WO2019113803A1/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the present invention relates to the field of medicine, and in particular to a compound for inhibiting EB virus-associated tumors, a preparation method thereof and use thereof.
  • Epstein-Barr virus is a human herpesvirus that is a major tumor-causing virus in addition to causing infectious mononucleosis. It was discovered in the 1960s with local Burkitt lymphoma in Africa. Later, it was discovered that Epstein-Barr virus is associated with nasopharyngeal carcinoma, Hodgkin's disease, and gastric adenocarcinoma. The Epstein-Barr virus first infects human oral epithelial cells and then infects B lymphocytes. Some virus-bearing B lymphocytes escape the immune response, and the Epstein-Barr virus enters the latent infection period. The latent-infected EB virus expresses a series of viral proteins, hiding surface antigens, causing parasitic cells to change, leading to immortalization and eventually cancer.
  • Epstein-Barr Virus Nuclear Antigen 1 (EBNA1) was expressed in each type of Epstein-Barr virus latent infection. Previous studies have shown that EBNA1 is necessary to maintain the survival of viruses and tumor cells. EBNA1 promotes viral replication and expression of other viral genes by binding to the origin of replication of viral DNA. Blocking the binding of EBNA1 to the origin of viral replication, such as the use of small molecules to competitively bind to the binding site of EBNA1 or replication origin, the use of gene editing to modify viral DNA, or the use of RNA to interfere with the synthesis of EBNA1, all of which replicate viral replication and tumor cell proliferation. It has an inhibitory effect.
  • the pyrrole-imidazole polyamide polypeptide has strong DNA sequence recognition specificity. It consists of pyrrole, imidazole derivatives and analogs, which can be chimeric on the DNA ditch, efficiently recognize and bind to the target DNA sequence, and interfere with the expression of related genes at the DNA level.
  • the Yasuda team at Nagoya University in Japan used different synthetic methods to synthesize polyamide molecules for viral DNA replication origin for inhibition of Epstein-Barr virus (Cancer Science. 2011, 102.12: 2221-2230).
  • This molecule recognizes 5 base pairs at the viral origin of replication and has a half-inhibitory concentration of 50 ⁇ mol/L against Epstein-Barr virus-containing mouse B95-8 cells.
  • the polyamide molecules synthesized by the method have less base pairs and poor specificity; the semi-inhibition concentration of the in vitro cell experiments is large, and it is not enough to advance to practical application.
  • the present invention provides a compound which efficiently and specifically inhibits EB virus-associated tumors and other diseases, which can solve the problem of difficulty in entry and off-target of small molecule drugs. And because of the characteristics of the existing polyamide molecules, the synthesis of new molecules to pair more base pairs enhances the specificity of the polyamide molecules.
  • One aspect of the present invention provides a compound for inhibiting EB virus-associated tumors and other diseases, and a pharmaceutically acceptable salt thereof, having the structure represented by Formula I,
  • Another aspect of the invention provides a process for the preparation of a compound of formula I, which comprises the steps of:
  • a 4-amino-1-methyl-2-carboxy-pyrrole, a 4-amino-1-methyl-2-carboxy-imidazole and two 4-amino groups are sequentially coupled to a solid phase resin.
  • step 1) is to remove the protecting group on the solid phase resin phenylhydrazine, and coupling one 4-amino-1-methyl-2-carboxy-pyrrole and one 4-amino-1-methyl-2- Carboxy-imidazole and 2 4-amino-1-methyl-2-carboxy-pyrroles.
  • step 1) or 3) is:
  • step 1) or 3) is:
  • step 1) is:
  • step 1) or 3 is:
  • step 2) is the activation of R-2-(9-fluorenylmethoxycarbonylamino)-4-tert-butoxycarbonylaminobutyric acid, and the amino coupling on the intermediate obtained in the step 1) Removing the tert-butoxycarbonyl protecting group;
  • step 3 the step of coupling 1-methyl-2-carboxy-imidazole in step 3) is:
  • the carboxyl group on 1-methyl--2-carboxylic acid-1H-imidazole is activated and coupled with the amino group on the intermediate obtained in the previous step of removing the protecting group; then the Fmoc protecting group is removed.
  • the 1-methyl-2-carboxylic acid-1H-imidazole and the condensing agent are dissolved in an organic solvent, and the alkaline agent is added to the reaction to completeness.
  • the intermediate obtained in the previous step is added, and the condensation reaction is completed to completion in an inert atmosphere;
  • the Fmoc protecting group was removed under 20% piperidine/DMF conditions.
  • step 4) is to activate compound A with a condensing agent and an alkali agent, and then react with the product obtained in step 3) to complete, and react with dimethylaminopropylamine and Cu(OAc) 2 to complete Purified to give the final product; the compound A is selected from the Hurst acid derivative Ht-1.
  • the condensing agent used in the present invention is selected from one or a combination of HATU, HOBt, HCTU, DCC, DIC, EDC, HBTU, HOAt, PyBOP, PyAOP, BOP-Cl, SOCl 2 , oxalyl chloride.
  • the alkaline agent of the present invention refers to a compound capable of providing an alkaline environment, and one or more selected from the group consisting of DIEA, trimethylpyridine, and triethylamine.
  • the EB virus-mediated tumor refers to EB virus-positive malignant lymphosarcoma, lymphoma, nasopharyngeal carcinoma, neuroblastoma, gastric cancer, colorectal cancer, and thymic lymphoid epithelial cancer.
  • Other diseases caused by Epstein-Barr virus refer to mononucleosis.
  • composition comprising a therapeutically effective amount of a compound of the invention or a pharmaceutically acceptable salt thereof.
  • the "therapeutically effective amount” refers to a dose administered to a subject for therapeutic purposes, which dose is capable of achieving the purpose of treating the corresponding disease.
  • the related tumor and other disease inhibitors caused by the EB virus of the present invention are pyrrole-imidazole polyamide polypeptides, which have a polyamide terminal and a ⁇ -aminobutyric acid hairpin structure, and can efficiently bind specifically to the origin of replication of viral DNA, specific Strong, can interfere with the binding of EBNA1 to the origin of replication, affect the function of EBNA1, and inhibit the expression of viral genes.
  • the simultaneous introduction of Ht-1 enhances the ability of polyamide molecules to penetrate biofilms and bind to target DNA, thereby inhibiting viral replication and leading to host cell death.
  • Figure 1 is a mass spectrum of a compound of formula I.
  • 2A is a comparison of the inhibitory effects of a compound of formula I against EB-related tumor cells and non-EB-related tumor cell proliferation.
  • Figure 2B is a comparison of the effect of a compound of formula I on the relative survival of EB-related tumor cells and non-EB-related tumor cells.
  • Figure 3A is a graph showing the results of the relative amounts of virus at different time points after the action of Formula I on Raji cells.
  • Figure 3B is a graph showing the results of the relative amounts of virus at different time points after the action of Formula I on Daudi cells.
  • Figure 4 is a graph showing the results of inhibition of viral DNA binding to EBNA1 by a compound of formula I.
  • Figure 5 is a graph showing the results of inhibition of viral expression products by a compound of formula I.
  • Figure 6A is a graph showing the results of tumor volume inhibition of viral tumor growth on tumor-bearing mice in a compound of formula I.
  • Figure 6B is a photograph of a tumor of a compound of formula I inhibiting the growth of a virus-bearing tumor on a tumor-bearing mouse.
  • step (b) Removal of Fmoc protecting group: 3 mL of 20% piperidine/DMF solution was added to the resin after the swelling of step (a), and N 2 was bubbled and mixed. After 10 minutes, the solvent was removed, and then 3 mL of 20% piperidine was added. /DMF solution, N 2 was bubbled and mixed, after 10 min, the resin was washed with DMF (4 ⁇ 3 mL), and the resin was washed with 3 mL of anhydrous DMF, and set aside;
  • Step (b) is used to remove the Fmoc protecting group in the peptide supported on the phenylhydrazine resin represented by formula (7);
  • the Hurst acid derivative Ht-1 (539 mg, 1.056 mmol) and PyBOP (550 mg, 1.056 mmol) were dissolved in 3 mL of anhydrous DMF, DIEA (350 ⁇ L, 2.112 mmol) was added, and the reaction was carried out for 5 min.
  • Hurst acid derivative Ht-1 is as follows (for preparation, see J.AM. CHEM. SOC. 2004, 126, 3736-3747):
  • the compound of formula I was cultured in complete RPMI-1640 medium at a drug concentration of 0 ⁇ M or 10 ⁇ M per well. Wells at a concentration of 0 ⁇ M were added to the same concentration of DMSO as a control. Incubate at 37 ° C in a 5% carbon dioxide cell incubator. On the third day, 2 ml of complete RPMI-1640 medium containing the same concentration of the compound of formula I was added to each well.
  • the mixed cell suspension was aspirated, stained with 0.4% trypan blue dye solution, and counted under a microscope to calculate the number of viable cells.
  • the compound of the formula I had a significant inhibitory effect on the growth of virus-containing Raji cells and Daudi cells, and had no significant inhibitory effect on the virus-free Jurkat cells and MOLT-4 cells.
  • the medium was discarded, and 100 ⁇ l of DMSO was added to dissolve the formazan produced by the cells, shaken on a shaker, and dissolved at 37 ° C for 30 minutes.
  • the absorbance at 450 nm was measured on a microplate reader and zeroed with DMSO as a blank.
  • the compound of the formula I had a significant inhibitory effect on the growth of virus-containing cells, and had no significant inhibitory effect on cells containing no virus.
  • Raji cells and Daudi cells carrying Epstein-Barr virus in logarithmic growth phase were seeded in a 6-well plate according to Raji's 500,000 per well and Daudi 1 million cells per well.
  • Incubate in 2 ml of complete RPMI-1640 medium containing the compound of formula I the drug concentration per well was 10 ⁇ M, and another 1 well was not added to the compound of formula I, and cultured in 2 ml of complete RPMI-1640 medium, only the same concentration was added.
  • the medium of DMSO was used as a control.
  • a blank control was collected in the same manner. After centrifugation at 500 xg for 5 minutes, the medium was discarded, the pellet was washed with 1 ml of PBS, and centrifuged at 500 x g for 5 minutes. use The total DNA of the cells was extracted by MicroElute Genomic DNA Kit. After measuring the DNA content by micro-spectrophotometer, the DNA was diluted to 10 ng/ ⁇ l, the Epstein-Barr virus replication origin was used as a template, and the human GAPDH gene was used as an internal control to detect the virus by real-time fluorescent quantitative PCR. The copy number of DNA (related sequences and primers are shown in Table 1), and the results are shown in Figures 3A and 3B. 3A and 3B, it can be explained that the compound of the formula I has an inhibitory effect on viral DNA in virus-containing cells, and the effect is increased with time.
  • Raji cells carrying Epstein-Barr virus in logarithmic growth phase were inoculated in a 150 mm dish at 8 million, 12 million and 12 million per dish, and cultured in 20 ml of complete RPMI-1640 medium containing the compound of formula I.
  • the drug concentrations were 0 ⁇ M, 10 ⁇ M and 10 ⁇ M, respectively.
  • a dish of 0 ⁇ M was added to the same concentration DMSO was used as a control.
  • one experimental dish and one control dish were taken; at 48 hours, another experimental dish was taken.
  • the cells were resuspended by gently pipetting, collected in a centrifuge tube, centrifuged at 250 x g for 5 minutes, and the supernatant was poured into the corresponding dish.
  • the cells were resuspended in 1 ml of the supernatant, stained with 0.4% trypan blue dye solution, and counted under a microscope to calculate the number of viable cells.
  • EBNA1 antibody (1 ⁇ g) was used to coprecipitate the cross-linking of EBNA1 protein and corresponding DNA.
  • the same amount of normal mouse IgG1 was used as a negative control antibody to detect whether the reaction was non-specific. opposite sex.
  • the co-precipitated DNA product was analyzed by real-time fluorescent quantitative PCR using the viral origin of replication as a template and compared to the total DNA of 2% Input. The result is shown in Figure 4.
  • Figure 4 illustrates that the compound of formula I inhibits the binding of EBNA1 to its binding site at in vivo levels compared to the control.
  • Raji cells carrying Epstein-Barr virus in logarithmic growth phase were seeded in 6-well plates at 500,000 cells per well.
  • the cells were cultured in 2 ml of complete RPMI-1640 medium containing the compound of formula I at concentrations of 0, 1, 2, 5, 10 and 20 ⁇ M per well. After 24 hours, the cells were resuspended by gently pipetting, transferred to a centrifuge tube, centrifuged at 500 x g for 5 minutes, the medium was discarded, the pellet was washed with 1 ml of PBS, centrifuged at 500 x g for 5 minutes, and the supernatant was discarded.
  • the membrane was blocked in 5% skim milk in PBST for 30 minutes at room temperature.
  • the EBNA1 antibody was configured at 1:500
  • the EBNA2 antibody was configured at 1:2000
  • the GAPDH antibody was configured at 1:5000, both in 5% skim milk in PBST solution.
  • the antibody was incubated with the above primary antibody and shaken at low speed overnight at 4 °C. Wash with PBST for 5 minutes each time. Thereafter, the corresponding species of HRP secondary antibody (1:5000, dissolved in 5% skim milk in PBST solution) was incubated and incubated for 1 hour at room temperature. Wash with PBST for 5 minutes each time.
  • the development exposure was then carried out using a multi-function imager, and the results are shown in FIG. Figure 5 shows that the compound of formula I inhibits both EBNA1 and EBNA2.
  • the expression of viral proteins, and the inhibition efficiency was positively correlated with the drug concentration, and did not significantly affect the expression of GAPDH protein.
  • Each mouse in the experimental group was injected with 20 nmol of the compound of the formula I in 100 ⁇ l of 5% DMSO/physiological saline solution.
  • the control group was injected with only 100 ⁇ l of 5% DMSO/physiological saline solution. Injections were repeated every 3 days and the size of the tumor was measured before injection. The results are shown in Figure 6A. Three days after the 8th injection, the mice were sacrificed, the tumor was exfoliated, and the observation was recorded. The results are shown in Fig. 6B. The results indicate that the compound of formula I has an inhibitory effect on the growth of viral tumors in tumor-bearing mice.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及一种用于抑制EB病毒相关肿瘤的化合物及其制备方法和用途，具体公开了一种用于抑制EB病毒相关肿瘤和其他疾病的化合物及其药学上可接受的盐，其具有式I所示的结构。还公开了式I所示化合物或者其药学上可接受盐在制备抑制EB病毒、EB病毒介导的肿瘤以及EB病毒介导的其他疾病的药物中的用途。本发明的化合物能够高效特异性结合在病毒DNA的复制起点上，特异性强，能够干扰EBNA1与复制起点的结合，影响EBNA1的功能，抑制病毒基因的表达。同时引入Ht-1，能够增强聚酰胺分子穿透生物膜的能力和结合目标DNA的能力，从而抑制病毒复制，导致宿主细胞死亡。

Description

用于抑制EB病毒相关肿瘤的化合物及其制备方法和用途 技术领域
本发明涉及医药领域，具体涉及用于抑制EB病毒相关肿瘤的化合物及其制备方法和用途。
背景技术
EB病毒是一种人类疱疹病毒，除了导致传染性单核细胞增多症以外，它还是一种主要的致肿瘤病毒。上世纪60年代时便发现它与非洲地方性Burkitt淋巴瘤有关，后来又陆续发现EB病毒与鼻咽癌、霍金奇病、胃腺癌等有关。EB病毒先感染人口腔上皮细胞，之后再感染B淋巴细胞。部分带病毒的B淋巴细胞会逃脱免疫反应，其中的EB病毒进入潜伏感染期。潜伏感染型的EB病毒会表达一系列病毒蛋白，隐藏表面抗原，使寄生的细胞发生改变，导致不朽化，最终引发癌症。
在各型EB病毒潜伏型感染中，均表达EB病毒核抗原1型(Epstein-Barr Virus Nuclear Antigen 1,EBNA1)。前人研究表明，EBNA1对维持病毒和肿瘤细胞的生存具有必要性。EBNA1通过与病毒DNA的复制起点结合，促进病毒的复制和病毒其他基因的表达。阻碍EBNA1与病毒复制起点的结合，如利用小分子竞争性结合EBNA1或复制起点的结合位点、利用基因编辑修饰病毒DNA或利用RNA干扰EBNA1的合成等，均对病毒的复制和肿瘤细胞的增殖有抑制作用。
在众多DNA小沟结合剂中，吡咯-咪唑聚酰胺多肽具有很强的DNA序列识别特异性。它由吡咯、咪唑的衍生物和类似物组成，能嵌合在DNA小沟上，高效特异性识别和结合在目标DNA序列，在DNA水平上干扰相关基因的表达。
日本名古屋大学的Yasuda小组采用不同的合成方法，合成了针对病毒DNA复制起点的聚酰胺分子，用于抑制EB病毒(Cancer Science.2011,102.12:2221-2230)。该分子能识别病毒复制起点上的5个碱基对，针对含EB病毒的小鼠B95-8细胞的半抑制浓度达到50μmol/L。该方法合成的聚酰胺分子识别的碱基对较少，特异性较差；体外细胞实验的半抑制浓度大，不足以推进到实际应用。
(1)已经上市的药物中尚未有针对EB病毒导致肿瘤的特效药，主要为传统化疗药物，如烷化剂、核苷酸类似物等。这些药物不具有靶向性，副作用较大。 (2)siRNA和反义寡核苷酸因为入胞困难而难以施行。(3)小分子药物脱靶效应明显，相应地特异性也较差。(4)已有的尝试使用聚酰胺类多肽的技术则存在着合成方法落后、识别碱基少、特异性低的问题。
发明内容
为了解决上述问题，本发明提供了一种高效特异性抑制EB病毒相关肿瘤及其他疾病的化合物，其能够解决小分子药物入胞困难和脱靶的问题。并且由于针对已有的聚酰胺分子的特点，合成新的分子以配对更多碱基对，增强了聚酰胺分子的特异性。
本发明一个方面提供了一种用于抑制EB病毒相关肿瘤和其他疾病的化合物及其药学上可接受的盐，其具有式I所示的结构，
Figure PCTCN2017115736-appb-000001
本发明另一个方面提供了式I化合物的制备方法，其包括如下步骤：
1)在固相树脂上依次偶联1个4-氨基-1-甲基-2-羧基-吡咯、1个4-氨基-1-甲基-2-羧基-咪唑和2个4-氨基-1-甲基-2-羧基-吡咯；
2)在步骤1)所得中间体末端的吡咯基的氨基上偶联2，4-二氨基丁酸的羧基；
3)在步骤2)所得中间体的2，4-二氨基丁酸的4位氨基上依次偶联3个 4-氨基-1-甲基-2-羧基-吡咯、1个1-甲基-2-羧基-咪唑；
4)并在步骤3)所得中间体上进行修饰赫斯特酸衍生物Ht-1，并裂解树脂，获得终产品。
其中，步骤1)为脱除固相树脂苯肼上的保护基，偶联1个4-氨基-1-甲基-2-羧基-吡咯、1个4-氨基-1-甲基-2-羧基-咪唑和2个4-氨基-1-甲基-2-羧基-吡咯。
优选地，步骤1)或3)中偶联4-氨基-1-甲基-2-羧基-吡咯的步骤为：
活化4-叔丁氧羰基氨基-1-甲基-2-羧酸-1H-吡咯上的羧基，并与脱除保护基的苯胺固相合成树脂或中间体上的氨基进行偶联；脱除叔丁氧羰基的氨基保护基；
更优选地，步骤1)或3)中偶联4-氨基-1-甲基-2-羧基-吡咯的步骤为：
4-叔丁氧羰基氨基-1-甲基-2-羧酸-1H-吡咯与三光气共同溶解于有机溶剂中，滴加三甲基吡啶，反应完全后，加入碱剂后与脱除保护基中间体上的氨基进行偶联混合，并在惰性气氛下至反应完全；TFA/苯酚/H2O(v:v:v＝92:5:2.5)混合溶液脱除叔丁氧羰基保护基。
优选地，步骤1)中偶联4-氨基-1-甲基-2-羧基-咪唑的步骤为：
活化4-叔丁氧羰基氨基-1-甲基-2-羧酸-1H-咪唑上的羧基，并与脱除保护基的苯胺固相合成树脂或中间体上的氨基进行偶联；脱除叔丁氧羰基的氨基保护基；
更优选地，步骤1)或3)中偶联4-氨基-1-甲基-2-羧基-咪唑的步骤为：
4-叔丁氧羰基氨基-1-甲基-2-羧基-咪唑与三光气共同溶解于有机溶剂中，滴加三甲基吡啶，反应完全后，加入碱剂后与脱除保护基的苯胺固相合成树脂或中间体上的氨基进行偶联混合，并在惰性气氛下至反应完全；TFA/苯酚/H2O(v:v:v＝92:5:2.5)混合溶液脱除叔丁氧羰基保护基。
在本发明的技术方案中，步骤2)为活化R-2-(9-芴甲氧羰基氨基)-4-叔丁氧羰基氨基丁酸，并于步骤1)所得中间体上的氨基偶联；脱除叔丁氧羰基保护基；
优选地，步骤2)为将R-2-(9-芴甲氧羰基氨基)-4-叔丁氧羰基氨基丁酸和三光气共同溶解于有机溶剂中，滴加三甲基吡啶，反应完全后，加入碱剂和缩合剂至反应完全，并与脱除保护基中间体上的氨基进行偶联混合，并在惰性气氛下至反应完全；TFA/苯酚/H2O(v:v:v＝92:5:2.5)混合溶液脱除叔丁氧羰基保护基。
在本发明的技术方案中，步骤3)中偶联1-甲基-2-羧基-咪唑的步骤为：
活化1-甲基--2-羧酸-1H-咪唑上的羧基，并与脱除保护基的前步所得中间体上的氨基进行偶联；随后脱除Fmoc保护基。
优选为，将1-甲基-2-羧酸-1H-咪唑和缩合剂溶于有机溶剂中，加入碱剂反应至完全，加入前步所得中间体中，在惰性气氛下缩合反应至完全；以20％哌啶/DMF条件脱除Fmoc保护基。
在本发明的技术方案中，步骤4)为将化合物A与缩合剂和碱剂进行活化，然后与步骤3)所得产物反应至完全，并与二甲氨基丙胺及Cu(OAc)2反应至完全，纯化得到最终产物；所述化合物A选自赫斯特酸衍生物Ht-1。
本发明中所用的缩合剂选自HATU、HOBt、HCTU、DCC、DIC、EDC、HBTU、HOAt、PyBOP、PyAOP、BOP-Cl、SOCl2、草酰氯中的一种或多种组合。
本发明所述的碱剂指能够提供碱性环境的化合物，选自DIEA、三甲基吡啶、三乙胺中的一种或多种。
本发明再一个方面提供了一种本发明所述的化合物或者其药学上可接受盐在制备抑制EB病毒介导的肿瘤以及EB病毒介导的其他疾病的药物中的用途。
在本发明的技术方案中，所述的EB病毒介导的肿瘤是指EB病毒阳性的恶性淋巴肉瘤、淋巴瘤、鼻咽癌、神经母细胞瘤、胃癌、结直肠癌、胸腺淋巴上皮癌。EB病毒导致的其他疾病指单核细胞增多症。
本发明再一个方面提供了一种药物组合物，其包括治疗有效量的本发明所述的化合物或者其药学上可接受盐。
在本发明中，所述的“治疗有效量的”指为了治疗目的向受试者施用的剂量，该剂量能够达到治疗相应疾病的目的。
有益效果
本发明的EB病毒导致的相关肿瘤及其他疾病抑制剂为吡咯-咪唑聚酰胺多肽，其具有聚酰胺末端和γ-氨基丁酸发卡结构，能够高效特异性结合在病毒DNA的复制起点上，特异性强，能够干扰EBNA1与复制起点的结合，影响EBNA1的功能，抑制病毒基因的表达。同时引入Ht-1，能够增强聚酰胺分子穿透生物膜的能力和结合目标DNA的能力，从而抑制病毒复制，导致宿主细胞死亡。
附图说明
图1为式I化合物的质谱图。
图2A为式I化合物针对EB相关肿瘤细胞和非EB相关肿瘤细胞增殖的抑制效果的比较。
图2B为式I化合物针对EB相关肿瘤细胞和非EB相关肿瘤细胞相对生存率一个影响的比较。
图3A为式I化合对Raji细胞的作用后不同时间点病毒相对含量的结果图。
图3B为式I化合对Daudi细胞的作用后不同时间点病毒相对含量的结果图。
图4为式I化合物抑制病毒DNA与EBNA1相结合的结果图。
图5为式I化合物抑制病毒表达产物的结果图。
图6A为式I化合物在荷瘤小鼠上抑制带病毒肿瘤生长的肿瘤体积结果图。
图6B为式I化合物在荷瘤小鼠上抑制带病毒肿瘤生长的肿瘤照片。
具体实施方式
实验例1 式I化合物的制备
(a)树脂溶胀：于一个10mL的固相反应器中加入400mg Fmoc保护的苯肼树脂(0.66mmol/g，0.264mmol)及3mL CH2Cl2，将树脂溶胀30min，抽除CH2Cl2，备用；
(b)脱除Fmoc保护基：将3mL 20％哌啶/DMF溶液加入步骤(a)溶胀后的树脂中，N2鼓泡混匀，10min后，抽除溶剂，再加入3mL 20％哌啶/DMF溶液，N2鼓泡混匀，10min后，用DMF(4×3mL)洗涤树脂，再用3mL无水DMF洗涤树脂，备用；
(c)氨基酸缩合：将4-叔丁氧羰基氨基-1-甲基-1H-吡咯-2-羧酸(254mg，1.056mmol)和三光气(BTC，128mg，0.433mmol)溶于2mL无水THF，向该溶液中缓慢滴加三甲基吡啶(collidine，488μL，3.696mmol)，反应立即产生大量白色沉淀，加完反应3min，再加入2mL DIEA/DMF溶液(5％,v/v)，白色沉淀完全消失，将该反应液转移到步骤(b)脱除保护基的苯肼树脂中，N2鼓泡混匀，缩合反应0.5～1h，抽除反应液，用DMF(4×3mL)洗涤树脂，备用；
(d)脱除叔丁氧羰基保护基：用CH2Cl2(2×3mL)洗涤，抽除CH2Cl2，加入3.0mL TFA/苯酚/H2O(v:v:v＝92:5:2.5)混合溶液脱除步骤(b)所得缩合产物上 的叔丁氧羰基保护基，2min后抽除溶剂，再次加入3.0mL TFA/苯酚/H2O(v:v:v＝92:5:2.5)混合溶液反应20min，用CH2Cl2(2×3mL)及DMF(4×3mL)洗涤树脂，再用3mL无水DMF洗涤树脂，备用；
采用步骤(a)，(b)，(c)和(d)，得到式(1)所示的负载在苯肼树脂上的肽；
Figure PCTCN2017115736-appb-000002
(e)氨基酸缩合：将4-叔丁氧羰基氨基-1-甲基-1H-咪唑-2-羧酸(255mg，1.056mmol)和三光气(128mg，0.433mmol)溶于1mL无水THF，向该溶液中缓慢滴加三甲基吡啶(488μL，3.696mmol)，反应立即产生大量白色沉淀，加完反应3min，加入HOAt(144mg，1.056mmol)，再加入2mL DIEA/DMF溶液(5％,v/v)，白色沉淀完全消失，将该反应液转移到步骤(f)所得式(3)所示的负载在苯肼树脂上的肽中，N2鼓泡混匀，缩合反应0.5～1h，抽除反应液，用DMF(4×3mL)洗涤树脂，备用；
(f)采用步骤(d)脱除负载在苯肼树脂上的肽中的Boc保护基，得到式(2)所示的负载在苯肼树脂上的肽；
Figure PCTCN2017115736-appb-000003
(g)重复脱保护及缩合护步骤(c)和(d)，其中，直至完成得到式(3)所示的负载在苯肼树脂上的肽的合成；
Figure PCTCN2017115736-appb-000004
(h)γ-氨基酸的缩合：将R-2-(9-芴甲氧羰基氨基)-4-叔丁氧羰基氨基丁酸(465mg，1.056mmol)和三光气(128mg，0.433mmol)溶于2mL无水THF，向该溶液中缓慢滴加三甲基吡啶(488μL，3.696mmol)，反应立即产生大量白色沉淀，加完反应1min，加入HOAt(144mg，1.056mmol)，再加入2mL DIEA/DMF溶液(5％,v/v)，反应5min，白色沉淀完全消失，将该反应液转移到式(3)所示的负载在苯肼树脂上的直链肽(NH2-Py-Py-Im-Py-苯肼树脂)中，N2鼓泡混匀，缩合反应0.5～1h，抽除反应液，用DMF(4×3mL)洗涤树脂，得到式(4)所示的负载在苯肼树脂上的肽；
Figure PCTCN2017115736-appb-000005
(i)脱除叔丁氧羰基保护基：用CH2Cl2(2×3mL)洗涤，抽除CH2Cl2，加入3.0mL TFA/苯酚/H2O(v:v:v＝92:5:2.5)混合溶液脱除步骤(h)所得产物上的叔丁氧羰基保护基，2min后抽除溶剂，再次加入3.0mL TFA/苯酚/H2O(v:v:v＝92:5:2.5)混合溶液反应20min，用CH2Cl2(2×3mL)及DMF(4×3mL)洗涤树脂，再用3mL无水DMF洗涤树脂，得式(5)所示的负载在苯肼树脂上的肽；
Figure PCTCN2017115736-appb-000006
(j)重复脱保护及缩合护步骤(c)和(d)，其中，直至完成得到式(6)所示的负载在苯肼树脂上的肽的合成；
Figure PCTCN2017115736-appb-000007
(k)末端氨基酸的缩合：将1-甲基-1H-咪唑-2-羧酸(132mg，1.056mmol)和PyBOP(550mg，1.056mmol)溶于3mL无水DMF，加入DIEA(350μL，2.112mmol)，反应5min，将该反应液转移到步骤(h)所得的式(4)所示的负载在苯肼树脂上的肽中，N2鼓泡混匀，缩合反应2h，抽除反应液，用DMF(4×3mL)洗涤树脂，得到式(7)所示的负载在苯肼树脂上的肽；
Figure PCTCN2017115736-appb-000008
采用步骤(b)脱除式(7)所示的负载在苯肼树脂上的肽中的Fmoc保护基；
将赫斯特酸衍生物Ht-1(539mg，1.056mmol)和PyBOP(550mg，1.056mmol)溶于3mL无水DMF，加入DIEA(350μL，2.112mmol)，反应5min，将该反应液转移到脱除Fmoc的式(7)所示的负载在苯肼树脂上的肽中，N2鼓泡混匀，缩合反应1h，抽除反应液，用DMF(4×3mL)洗涤树脂；将树脂取出，加入1mL DMF、200μL二甲氨基丙胺及10mg Cu(OAc)2，室温振摇反应12h，将树脂滤除，并用20mL CH2Cl2洗涤树脂；将有机相浓缩，残留物用半制备型HPLC纯化：10％乙腈-H2O(含1％的TFA)等梯度洗脱5min，10％至100％的乙腈-H2O(含1％的TFA)梯度洗脱25min，保留时间TR＝18.5min，收集产物，冷冻干燥，得到式(8)所示的淡黄色固体化合物，HRMS(ESI)m/z:理论计算值C84H96N27O11[M+H]+1658.7777,实测:1658.7794。
Figure PCTCN2017115736-appb-000009
赫斯特酸衍生物Ht-1的结构如下(制备方法参见J.AM.CHEM.SOC.2004,126,3736-3747)：
Figure PCTCN2017115736-appb-000010
实验例2 式I化合物对带EB病毒的肿瘤细胞生长的抑制作用
取处于对数生长期的携带EB病毒的Raji细胞和Daudi细胞，以及不含病毒的Jurkat细胞和MOLT-4细胞，按每孔50万个细胞接种于6孔板中，分别在2ml含有不同浓度的式I化合物的完全RPMI-1640培养基中培养，使每孔的药物浓度分别为0μM或10μM。浓度为0μM的孔加入相同浓度的DMSO作为对照。置于37℃，5％二氧化碳细胞培养箱中培养。第三天时，再在每孔中加入2ml含相同式I化合物浓度的完全RPMI-1640培养基。第三天加入新培养基之前及第六天时，分别吸取混匀的细胞悬液，用0.4％台盼蓝染液染色，在显微镜下计数，计算活细胞数量。结果如图2A和图2B所示，式I化合物对含病毒的Raji细胞和Daudi细胞的生长有明显抑制作用，对不含病毒的Jurkat细胞和MOLT-4细胞则无明显抑制作用。
取处于对数生长期的携带EB病毒的Raji细胞、Daudi细胞和B95-8细胞，以及不含病毒的Jurkat细胞、MOLT-4细胞、RPMI-8226细胞、Nalm-6细胞和MDA-MB-231细胞。每孔以合适数量(MDA-MB-231为4000，其他为7000)和100μl合适培养基(MDA-MB-231为完全DMEM高糖培养基，其他为完全RPMI-1640培养基)接种于96孔板中。MDA-MB-231细胞接种后需等待细胞贴壁。之后加入100μl含不同浓度的式I化合物的合适培养基，使每孔化合物浓度为0μM、5μM、10μM和20μM，每浓度设4个复孔。浓度为0μM的孔加入相同浓度的DMSO作为对照。在37℃，5％二氧化碳培养箱中培养72小时后，每孔加入20μl10％MTT的PBS溶液，在37℃，5％二氧化碳培养箱中孵育30分钟。对Raji等悬浮细胞，将96孔板在大型离心机中以1000rpm离心5分钟。弃去培养基，加入100μl DMSO溶解细胞生成的甲瓒，在摇床上摇匀，置于37℃下溶解30分钟。在酶标仪上检测450nm处吸光值，以DMSO为空白调零。结果如图2B所示，式I化合物对含病毒细胞的生长有明显抑制作用，对不含病毒的细胞则无明显抑制作用。
实验例3 式I化合物对带EB病毒的肿瘤细胞中病毒DNA的抑制
取处于对数生长期的携带EB病毒的Raji细胞和Daudi细胞，按Raji每孔50万个，Daudi每孔100万个细胞接种于6孔板中。在2ml含有式I化合物的完全RPMI-1640培养基中培养，每孔的药物浓度分别为10μM，另取1孔不加入式I化合物，以2ml完全RPMI-1640培养基培养，仅加入含相同浓度的DMSO的培养基作为对照。置于37℃，5％二氧化碳细胞培养箱中培养。每24小时，轻轻吹打一孔，重悬细胞，收集至离心管中。第24h时按照同样的方法收集空白对照。500×g离心5分钟，弃去培养基，用1ml PBS清洗沉淀，500×g离心5分钟。用
Figure PCTCN2017115736-appb-000011
MicroElute Genomic DNA Kit提取细胞总DNA，用微量分光光度计测定DNA含量后，将DNA稀释至10ng/μl，以EB病毒复制起点为模板，以人GAPDH基因作为内对照，用实时荧光定量PCR检测病毒DNA的拷贝数(相关序列及引物见附表1)，结果如图3A和图3B所示。图3A和图3B可以说明，式I化合物对含病毒的细胞中的病毒DNA有抑制作用，作用效果随时间延长而增加。
实验例4 式I化合物在体内水平对EB病毒DNA与EBNA1结合的抑制
取处于对数生长期的携带EB病毒的Raji细胞，按每皿800万，1200万和1200万接种于150mm皿中，以20ml含有式I化合物的完全RPMI-1640培养基中培养，使每孔的药物浓度分别为0μM，10μM和10μM。浓度为0μM的皿加入相同浓度的 DMSO作为对照。24小时时，取一个实验组皿和对照组皿；48小时时，取另一个实验组皿。轻轻吹打重悬细胞，收集到离心管中，250×g离心5分钟，将上清液倒入对应的皿中。用1ml上清重悬细胞，用0.4％台盼蓝染液染色后在显微镜下计数，计算活细胞数量。
每组取800万个细胞，加回对应的培养皿中，振荡混匀。再加入540μl 37％甲醛，快速振荡混匀，固定10分钟。之后加入2ml 1.25M甘氨酸终止固定细胞。4℃下500×g离心5分钟，弃上清，用20ml冰PBS清洗沉淀两次，以同样的离心条件离心弃上清。之后用
Figure PCTCN2017115736-appb-000012
Enzymatic Chromatin IP Kit(Magnetic Beads)进行染色质免疫共沉淀实验，以EBNA1抗体(1μg)共沉淀EBNA1蛋白和对应DNA的交联，以等量普通小鼠IgG1为阴性对照抗体，检测反应是否具有非特异性。共沉淀得到的DNA产物以病毒复制起点为模板，与2％Input的总DNA相比，用实时荧光定量PCR分析其相对含量。结果如图4所示。图4可以说明，与对照组相比，在体内水平，式I化合物抑制了EBNA1与其结合位点的结合。
实验例5 式I化合物对肿瘤细胞病毒表达产物的抑制
取处于对数生长期的携带EB病毒的Raji细胞，按每孔50万个细胞接种于6孔板中。在2ml含有式I化合物的完全RPMI-1640培养基中培养，每孔的药物浓度分别为0,1,2,5,10和20μM。24小时后，轻轻吹打重悬细胞后，转移到离心管中，500×g离心5分钟，弃去培养基，用1ml PBS清洗沉淀，500×g离心5分钟，弃上清。
加入50μl含有1％蛋白酶抑制剂的1％Triton X-100裂解液，在冰上裂解20min，之后用超声波破碎仪85W破碎10秒。4℃下20000×g离心20分钟，取上清，即蛋白提取液。
利用BCA法进行蛋白定量后，每组取20μg总蛋白，加入loading buffer，沸水浴10分钟变性后，在8％SDS-PAGE分离胶和5％SDS-PAGE浓缩胶上点样，80-100V电泳分离蛋白样品，100V 90分钟转膜至PVDF膜上。
将膜在5％脱脂牛奶的PBST溶液中，室温封闭30分钟。以1:500配置EBNA1抗体，以1:2000配置EBNA2抗体，以1:5000配置GAPDH抗体，均溶于5％脱脂牛奶的PBST溶液中。用上述一抗孵育抗体，在4℃下低速摇床过夜。用PBST清洗，每次5分钟。之后孵育对应种属的HRP二抗(1:5000，溶于5％脱脂牛奶的PBST溶液中)，室温孵育1小时。用PBST清洗，每次5分钟。之后用多功能成像仪进行显影曝光，结果如图5所示。图5表明，式I化合物抑制了EBNA1和EBNA2这两 种病毒蛋白的表达，且抑制效率与药物浓度呈正相关，此外并没有对GAPDH蛋白的表达产生明显影响。
实验例6 式I化合物在荷瘤小鼠上对带病毒肿瘤生长的抑制
取对数期生长的Raji细胞和4-5周龄的Balb/c nu小鼠。250×g离心5分钟收集细胞，弃上清，用PBS清洗沉淀，同样条件离心，弃上清，用不含FBS的RPMI培养基重悬细胞，每100μl培养基含1×107个细胞。每只小鼠在侧肋皮下注射1×107个细胞。待肿瘤体积达到约100mm3(体积估计公式：V＝L×W2)时，开始给药。实验组每只小鼠瘤周注射20nmol式I化合物，溶于100μl 5％DMSO/生理盐水溶液中。对照组仅注射100μl 5％DMSO/生理盐水溶液。每3天重复注射，并在注射前测量肿瘤的尺寸，结果见图6A。注射第8次后三天，处死小鼠，剥出肿瘤，记录观察，结果见图6B。结果表明，式I化合物在荷瘤小鼠上对带病毒肿瘤的生长具有抑制作用。

Claims (10)

  1. 一种用于抑制EB病毒相关肿瘤和其他疾病的化合物及其药学上可接受的盐，其具有式I所示的结构，
    Figure PCTCN2017115736-appb-100001
  2. 式I化合物的制备方法，其包括如下步骤：
    1)在固相树脂上依次偶联1个4-氨基-1-甲基-2-羧基-吡咯、1个4-氨基-1-甲基-2-羧基-咪唑和2个4-氨基-1-甲基-2-羧基-吡咯；
    2)在步骤1)所得中间体末端的吡咯基的氨基上偶联2，4-二氨基丁酸的羧基；
    3)在步骤2)所得中间体的2，4-二氨基丁酸的4位氨基上依次偶联3个4-氨基-1-甲基-2-羧基-吡咯、1个1-甲基-2-羧基-咪唑；
    4)并在步骤3)所得中间体上进行修饰赫斯特酸衍生物Ht-1，并裂解树脂，获得终产品。
    其中，步骤1)为脱除固相树脂苯肼上的保护基，偶联1个4-氨基-1-甲基-2-羧基-吡咯、1个4-氨基-1-甲基-2-羧基-咪唑和2个4-氨基-1-甲基-2-羧基-吡咯。
  3. 根据权利要求2所述的制备方法，其中，步骤1)或3)中偶联4-氨基-1-甲基-2-羧基-吡咯的步骤为：
    活化4-叔丁氧羰基氨基-1-甲基-2-羧酸-1H-吡咯上的羧基，并与脱除保护基的苯肼固相合成树脂上的肼基或中间体上的氨基进行偶联；脱除叔丁氧羰基的氨基保护基；
    优选地，步骤1)或3)中偶联4-氨基-1-甲基-2-羧基-吡咯的步骤为：
    4-叔丁氧羰基氨基-1-甲基-2-羧酸-1H-吡咯与三光气共同溶解于有机溶剂 中，滴加三甲基吡啶，反应完全后，加入碱剂后与脱除保护基中间体上的氨基进行偶联混合，并在惰性气氛下至反应完全；TFA/苯酚/H2O混合溶液脱除叔丁氧羰基保护基。
  4. 根据权利要求2所述的制备方法，步骤1)中偶联4-氨基-1-甲基-2-羧基-咪唑的步骤为：
    活化4-叔丁氧羰基氨基-1-甲基-2-羧酸-1H-咪唑上的羧基，并与脱除保护基的苯肼固相合成树脂上的肼基或中间体上的氨基进行偶联；脱除叔丁氧羰基的氨基保护基。
  5. 根据权利要求2所述的制备方法，步骤1)或3)中偶联4-氨基-1-甲基-2-羧基-咪唑的步骤为：
    4-叔丁氧羰基氨基-1-甲基-2-羧基-咪唑与三光气共同溶解于有机溶剂中，滴加三甲基吡啶，反应完全后，加入碱剂后与脱除保护基的苯肼固相合成树脂上的肼基或中间体上的氨基进行偶联混合，并在惰性气氛下至反应完全；TFA/苯酚/H2O混合溶液脱除叔丁氧羰基保护基。
  6. 根据权利要求2所述的制备方法，步骤2)为活化R-2-(9-芴甲氧羰基氨基)-4-叔丁氧羰基氨基丁酸，并于步骤1)所得中间体上的氨基偶联；脱除叔丁氧羰基保护基；
    优选地，步骤2)为将R-2-(9-芴甲氧羰基氨基)-4-叔丁氧羰基氨基丁酸和三光气共同溶解于有机溶剂中，滴加三甲基吡啶，反应完全后，加入碱剂和缩合剂至反应完全，并与脱除保护基中间体上的氨基进行偶联混合，并在惰性气氛下至反应完全；TFA/苯酚/H2O混合溶液脱除叔丁氧羰基保护基。
  7. 根据权利要求2所述的制备方法，步骤3)中偶联1-甲基-2-羧基-咪唑的步骤为：
    活化1-甲基-2-羧酸-1H-咪唑上的羧基，并与脱除保护基的前步所得中间体上的氨基进行偶联；随后脱除Fmoc保护基。
  8. 式I所示化合物或者其药学上可接受盐在制备抑制EB病毒、EB病毒介导的肿瘤以及EB病毒介导的其他疾病的药物中的用途。
  9. 根据权利要求8所述的用途，EB病毒介导的肿瘤是指EB病毒阳性的恶性淋巴肉瘤、淋巴瘤、鼻咽癌、神经母细胞瘤、胃癌、结直肠癌、胸腺淋巴上皮癌；EB病毒介导的其他疾病为单核细胞增多症。
  10. 一种药物组合物，其包括治疗有效量的式I所述化合物或者其药学上可接受盐以及药学上可接受的载体。
PCT/CN2017/115736 2017-12-12 2017-12-12 用于抑制eb病毒相关肿瘤的化合物及其制备方法和用途 WO2019113803A1 (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN2017/115736 WO2019113803A1 (zh) 2017-12-12 2017-12-12 用于抑制eb病毒相关肿瘤的化合物及其制备方法和用途

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2017/115736 WO2019113803A1 (zh) 2017-12-12 2017-12-12 用于抑制eb病毒相关肿瘤的化合物及其制备方法和用途

Publications (1)

Publication Number Publication Date
WO2019113803A1 true WO2019113803A1 (zh) 2019-06-20

Family

ID=66819818

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/115736 WO2019113803A1 (zh) 2017-12-12 2017-12-12 用于抑制eb病毒相关肿瘤的化合物及其制备方法和用途

Country Status (1)

Country Link
WO (1) WO2019113803A1 (zh)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106674209A (zh) * 2016-12-23 2017-05-17 深圳先进技术研究院 程序性死亡受体1基因抑制剂及其制备方法与应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106674209A (zh) * 2016-12-23 2017-05-17 深圳先进技术研究院 程序性死亡受体1基因抑制剂及其制备方法与应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AI YASUDA: "DNA ligand designed to antagonize EBNA1 represses Epstein- Barr virus-induced immortalization", CANCER SCIENCE, vol. 102, no. 12, 31 December 2011 (2011-12-31), pages 2221 - 30, XP055617671 *

Similar Documents

Publication Publication Date Title
JP4682140B2 (ja) Ｃ型肝炎インヒビターペプチド類縁体
JP4550824B2 (ja) Ｃ型肝炎抑制化合物
TW577895B (en) Hepatitis C inhibitor peptides
TWI327145B (en) Hepatitis c inhibitor compounds
JP4682155B2 (ja) Ｃ型肝炎ウイルスに対して活性な大環状ペプチド
JP3494624B2 (ja) 新規な環状テトラペプチド誘導体とその医薬用途
EA003906B1 (ru) Трипептидные ингибиторы вируса гепатита c
WO2009053828A2 (en) P3 hydroxyamino macrocyclic hepatitis c serine protease inhibitors
HU227742B1 (en) Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
JP2011006420A (ja) Ｃ型肝炎ウイルスに対し活性な大環状ペプチド
TW200826938A (en) Hepatitis C virus inhibitors
KR20090017688A (ko) 마크로사이클릭 옥시밀 ｃ형 간염 프로테아제 억제제
CA2746264A1 (en) New 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
IL296994A (en) compounds and their uses
CN103304631A (zh) 具有抗肿瘤活性的九肽
CN113663067A (zh) 免疫激活型抗体及其应用
WO2019113803A1 (zh) 用于抑制eb病毒相关肿瘤的化合物及其制备方法和用途
CN109912577B (zh) 用于抑制eb病毒相关肿瘤的化合物及其制备方法和用途
WO2014119753A4 (ja) マイオスタチン阻害ペプチド
JP2877909B2 (ja) 置換アスパラギン酸側鎖を有する抗ヘルペスペンタペプチド誘導体
WO2019034175A1 (zh) 一种非天然鹅膏毒肽类抗体偶联物
CN117529490A (zh) 用于将药物递送至肝细胞的环状肽-N-乙酰半乳糖胺（GalNAc）缀合物
US20180370909A1 (en) Inhibitors of tnf superfamily costimulatory interactions and methods for uses of the same
JPS6327360B2 (zh)
JP2877908B2 (ja) 抗ヘルペスペンタペプチド類

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17934757

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205 DATED 12/11/2020)

122 Ep: pct application non-entry in european phase

Ref document number: 17934757

Country of ref document: EP

Kind code of ref document: A1